Rheumatology Enrollment Form Medications A (Actemra®)

CVS specialty

Fax Referral To: 1-888-280-1191 OR 787-759-4161 Phone: 1-888-280-1190 OR 787-759-4162 Email Referral To: customerservicefax@caremark.com

		Address: 280 Avenida Jesus			
		Six Simple Steps		g a Referral	
1 PATIENT I	INFORMATION (Comp	olete or include demog	graphic sheet)		
Patient Name: _		Address:		City, State, ZIP:	
Preferred Contac	ct Methods: 🗌 Phone (to pr	imary # provided belo	w) 🗌 Text (to d	cell # provided below) 🗌 Email (to e	email provided below)
Note: Carrier cha	arges may apply. If unable t	o contact via text or er	nail, Specialty	Pharmacy will attempt to contact by	phone.
Primary Phone: _	Alterna	te Phone:	DOB:	Gender: 🗌 Ma	ale 🗌 Female
<u>E</u> mail:		Last Four of S	3SN:	Primary Language:	
2 PRESCRIE	BER INFORMATION				
 Prescriber's Nan	ne:		State License #	‡ :	
NPI #:	DEA #:	Group or Ho	spital:	# :	
Address:			City, State, ZI	P:	
Phone:	Fax	Conta	act Person:	P: Contact's Phone	: <u></u>
3 INSURAN	CE INFORMATION	Please fax copy of pre	scription and ir	surance cards with this form, if avai	ilable (front and back)
	IS AND CLINICAL II		•	,	,
	Ship to: ☐ Patie				
Diagnosis (ICD-					
	natoid Arthritis, Unspecified		□ м4.5	5.9 Ankylosing Spondylitis of Unspe	cified Sites in Spine
	pathic Psoriasis, Unspecific	ed	☐ L40	5.9 Ankylosing Spondylitis of Unspe .59 Other Psoriatic Arthropathy	omod ontoo iii opiiio
				er Code: Description	
•	D-10 information, please vis				
	specialty.com/wps/portal/spe				
Patient Clinical	Information:				
Allergies:	<u> </u>	Weight:Ib/k	κg Height:	in/cm TB Test Result:	Date:
Nursing:					
				isit necessary ☐ Yes ☐ No	
	MD office Infusion Clinic	•		alth	
	not necessary. Date training				
	office training patient Pt		□ Referred by	MD to alternate trainer	
	PTION INFORMATION	N			
MEDICATION	STRENGTH		DOSE & DIRE		QUANTITY/REFILLS
	□ 80 mg/4 mL	Induction Dose: In			Quantity:
☐ Actemra	☐ 200 mg/10 mL ☐ 400 mg/20 mL	☐ Maintenance Dos	<u>se:</u> intuse 8 mg.	/kg every 4 weeks.	Refills:
	· ·		hina <100ka: I	nject 162mg SC every other week,	Quantity:
☐ Actemra	162mg/0.9 mL prefilled			eek based on clinical response	Refills:
	syringe	☐ For patients weig	hing ≥ 100kg:	Inject 162mg SC every week.	
	by freely and voluntarily have selectent Signature:			to dispense the medication herein prescribed by	
⊢atiei □ Pati	ient is interested in patient support programs	STAMP SIGNA	TURE NOT ALLOWED	Ancillary supplies and kits provided as needed	for administration
		PHYSICIAN SIG	INDTHE F	SEULIIBED	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

DISPENSE AS WRITTEN

(Date)

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

(Date)

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.

©2020 CVS Pharmacy, Inc. or one of its affiliates. 75-38703A 071620

PRODUCT SUBSTITUTION PERMITTED

Medications A-C Rheumatology Enrollment Form

(Avsola™Cimzia®,Cosentyx®)

		plete Patient and Prescriber information	
Patient Name: _		Patient DOB:	_
Prescriber Nam		Prescriber Phone:	_
5 PRESCR	RIPTION INFORMATION		
MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
Avsola	100 mg vial	☐Rheumatoid Arthritis Induction Dose: In conjunction with methotrexate Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter. ☐ Rheumatoid Arthritis Maintenance Dose: Infuse 3 mg/kg every 8 weeks.	Quantity: # of 100 mg vial Refills:
		☐ Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter. ☐ Psoriatic Arthritis Maintenance Dose: Infuse 5 mg/kg every 8 weeks. ☐ Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 6 weeks thereafter. ☐ Ankylosing Spondylitis Maintenance Dose: Infuse 5 mg/kg every 6 weeks.	
☐ Cimzia	Cimzia Starter Kit (6 prefilled syringes)	Other: Induction Dose: 400 mg initially and at week 2 and 4, (given as 2 SC of 200 mg each) followed by 200 mg every other week;	Quantity: 1 Kit Refills: 0
☐ Cimzia	☐ 200mg/1 mL prefilled syringe ☐ 200mg vial	 	Quantity: Refills:
☐ Cosentyx	☐ Sensoready® pen 150 mg/mL injection ☐ Prefilled syringe 150 mg/mL injection	Psoriatic Arthritis with Coexistent Moderate to Severe Plaque Psoriasis Loading Dose: Inject 300 mg (two injections) SC at weeks 0, 1, 2, 3 and 4. Maintenance Dose: Inject 300 mg (two injections) SC every 4 weeks. Other Psoriatic Arthritis or Ankylosing Spondylitis With Loading Dose: Inject 150 mg (one injection) SC at weeks 0, 1, 2, 3 and 4, and then every 4 weeks thereafter. Without Loading Dose: Inject 150 mg (one injection) SC every 4 weeks. Other:	Quantity:Refills:
Pa D	atient Signature: Patient is interested in patient support programs 6 PHYS RODUCT SUBSTITUTION PERMITTED	mark and/or CarePlus CVS/pharmacy to dispense the medication herein prescribed by m STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits provided as needed for SICIAN SIGNATURE REQUIRED (Date) DISPENSE AS WRITTEN (Date) X	or administration

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.

©2020 CVS Pharmacy, Inc. or one of its affiliates. 75-38703A 071620

Medications E-I Rheumatology Enrollment Form

(Enbrel®, Humira®, Ilaris®,Inflectra®)

		complete Patient and Prescriber information	
Patient Name: _			_
Prescriber Name		Prescriber Phone:	_
	RIPTION INFORMATIO	N	
MEDICATION		DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Enbrel	□ 25mg/0.5 mL prefilled syringe □ 25mg vial □ 50mg/mL Sureclick TM Autoinjector □ 50mg/mL prefilled syringe □ 50 mg/mL Enbrel Mini™ prefilled cartridge for use with the AutoTouch™ reusable autoinjector only (Prescriber MUST supply). CVS does not order the autoinjector.	☐ Inject 25mg SC TWICE a week (72 – 96 hours apart). ☐ Inject 50mg SC ONCE a week. ☐ Other:	Quantity:Refills:
☐ Humira	☐ 40 mg/0.4 mL Pen Citrate Free ☐ 40 mg/0.4 mL Prefilled Syringe Citrate Free	☐ Inject 40mg SC every OTHER week. ☐ Other:	Quantity: Refills:
□ Ilaris	150 mg/mL injection solution	For patients weighing ≥ 7.5 kg: Inject 4 mg/kg (with a maximum of 300 mg) SC every 4 weeks. Each single-dose vial of ILARIS (canakinumab) Injection delivers 150 mg/mL sterile, preservative-free, clear to slightly opalescent, colorless to a slight brownish to yellow solution.	Quantity: Refills:
☐ Inflectra	100 mg vial	☐ Rheumatoid Arthritis Induction Dose: In conjunction with methotrexate Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter. ☐ Rheumatoid Arthritis Maintenance Dose: Infuse 3 mg/kg every 8 weeks. ☐ Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter. ☐ Psoriatic Arthritis Maintenance Dose: Infuse 5 mg/kg every 8 weeks. ☐ Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 6 weeks thereafter. ☐ Ankylosing Spondylitis Maintenance Dose: Infuse 5 mg/kg every 6 weeks. ☐ Ankylosing Spondylitis Maintenance Dose: Infuse 5 mg/kg every 6 weeks. ☐ Other: _	Quantity: # of 100 mg vial Refills:
Patient □ Patien	t Signature:nt is interested in patient support programs	S Caremark and/or CarePlus CVS/pharmacy to dispense the medication herein prescribed by STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits provided as need PHYSICIAN SIGNATURE REQUIRED (Date) DISPENSE AS WRITTEN X	_

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.

©2020 CVS Pharmacy, Inc. or one of its affiliates. 75-38703A 071620

Medications K-O Rheumatology Enrollment Form

(Kevzara®,Olumiant®,Orencia®, Otezla®)

Patient Name:		e complete Patient and Prescriber information Patient DOB:	_
Prescriber Name:	_		
PRESCRI	PTION INFORMATIO	N	
MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Kevzara	☐ 200 mg/1.14 mL prefilled syringe (pk of 2) ☐ 150 mg/1.14 mL prefilled syringe (pk of 2) ☐ 200 mg/1.14 mL prefilled pen (pk of 2) ☐ 150 mg/1.14 mL prefilled pen (pk of 2)	☐ Inject 200 mg SC once every two weeks. ☐ Inject 150 mg SC once every two weeks.	Quantity: Refills:
Olumiant	2 mg tablet 1 mg tablet	☐ Take 2 mg PO once daily ☐ Other:	Quantity:Refills:
☐ Orencia	☐ 125mg prefilled syringe ☐ ClickJect Autoinjector 125 mg/mL pack of 4	☐ Inject 125mg SC every week ☐ After Single IV Loading Dose: Inject 125mg SC within a day and 125mg SC every week thereafter. ☐ Patients Unable to Receive an IV Loading Dose: Inject 125 mg SC every week. ☐ Patients Transitioning from IV Infusion Therapy: Inject 125 mg SC instead of the next scheduled IV dose, followed by 125mg SC injections every week thereafter.	Quantity:Refills:
Orencia	250 mg vial	☐ Infuse mg at weeks 0, 2 and 4, then every 4 weeks thereafter. ☐ Other:	Quantity:Refills:
☐ Otezla	Titration Starter Pack	Day 1: 10 mg PO in the morning. Day 2: 10 mg PO in the morning and 10 mg PO in the evening. Day 3: 10 mg PO in the morning and 20 mg PO in the evening. Day 4: 20 mg PO in the morning and 20 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 6 and thereafter: 30 mg PO twice daily.	Quantity: 1 Pack Refills: 0
☐ Otezla	30 mg tablet	☐ Maintenance Dose: 30 mg PO twice daily. ☐ Other:	Quantity: Refills:
Patient Signs		S Caremark and/or CarePlus CVS/pharmacy to dispense the medication herein prescribe STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits provided as	
PRODUCT SU	BSTITUTION PERMITTED	HYSICIAN SIGNATURE REQUIRED (Date) DISPENSE AS WRITTEN X the best of my knowledge, with supporting documentation in the patient's medical re	(Date)

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.

©2020 CVS Pharmacy, Inc. or one of its affiliates. 75-38703A 071620

Medications R-S

Rheumatology Enrollment Form

(Remicade®, Renflexis®, Rinvoq®, Rituxan®, Simponi®)

Dationt Name:		e complete Patient and Prescriber information	
Prescriber Name:		Patient DOB: Prescriber Phone:	_
			_
MEDICATION	PTION INFORMATIO	DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Remicade	100 mg vial	☐ Rheumatoid Arthritis Induction Dose: In conjunction with methotrexate Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter. ☐ Rheumatoid Arthritis Maintenance Dose: Infuse 3 mg/kg every 8 weeks. ☐ Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter. ☐ Psoriatic Arthritis Maintenance Dose: Infuse 5 mg/kg every 8 weeks. ☐ Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 6 weeks thereafter. ☐ Ankylosing Spondylitis Maintenance Dose: Infuse 5 mg/kg every 6 weeks. ☐ Other:	Quantity:Refills:
Renflexis	100 mg vial	□ Rheumatoid Arthritis Induction Dose: In conjunction with methotrexate Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter. □ Rheumatoid Arthritis Maintenance Dose: Infuse 3 mg/kg every 8 weeks. □ Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter. □ Psoriatic Arthritis Maintenance Dose: Infuse 5 mg/kg every 8 weeks. □ Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, week 2, week 6 and every 6 weeks thereafter. □ Ankylosing Spondylitis Maintenance Dose: Infuse 5 mg/kg every 6 weeks. □ Other:	Quantity: # of 100 mg vial Refills:
Rinvoq	15 mg	☐ Take one 15 mg tablet PO once daily. ☐ Other:	Quantity:Refills:
Rituxan	☐ 100 mg/10 mL vial ☐ 500 mg/50 mL vial	☐ Infuse two doses of 1000 mg separated by 2 weeks. ☐ Other:	Quantity:Refills:
Simponi	☐ 50mg/0.5mL prefilled SmartJect® Autoinjector ☐ 50mg/0.5mL prefilled syringe	☐ Inject 50mg SC once a month. ☐ Other:	Quantity: Refills:
	freely and voluntarily have selected C' Signature:	VS Caremark and/or CarePlus CVS/pharmacy to dispense the medication herein prescribed by	my physician.
□ Patient	is interested in patient support programs	STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits provided as neede	ed for administration
DDODU	6 I	PHYSICIAN SIGNATURE REQUIRED (Date) DISPENSE AS WRITTEN ((Date)
X	OF GODOTHOLION FERIVITIED	(Date) DISPENSE AS WRITTEN (Date)
			

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.

Medications S-Z

Rheumatology Enrollment Form (Simponi ARIA®, Stelara®, Taltz®,Tremfya® ,Xeljanz®)

D. (; ();			Please	complete Patient and Prescriber information	
Patient Name:					
Prescriber Name: PRESCRI		INFORM	ΙΔΤΙΩ	Prescriber Phone: N	
MEDICATION		TRENGTH		DOSE & DIRECTIONS	QUANTITY/REFILLS
☐ Simponi ARIA		l mL in a sir		Infuse 2 mg/kg over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter.	Quantity: # of 50 mg vial Refills:
☐ Stelara	☐ 45mg/0.5mL prefilled syringe ☐ 90mg/mL prefilled syringe			☐ For patients weighing ≤100 kg (220 lbs): Inject 45 mg SC initially and 4 weeks later, followed by 45 mg every 12 weeks. ☐ For patients weighing >100 kg (220 lbs): Inject 90 mg SC initially and 4 weeks later, followed by 90 mg every 12 weeks. ☐ Other:	Quantity:Refills:
☐ Taltz	Autoinje	ng Single Do ector ng Single Do I Syringe		Psoriatic Arthritis with Coexistent Moderate to Severe Plaque Psoriasis Dosing: Starting Dose: Inject SC two 80 mg injections on Day 1, then begin the induction dose 2 weeks later. Induction Dose: Inject SC one 80 mg injection every 2 weeks (weeks 2, 4, 6, 8, 10, and 12). Maintenance Dose: Inject SC one 80 mg injection every 4 weeks.	☐ 3 Pens/Syringes ☐ 2 Pens/Syringes ☐ 1 Pens/Syringes Refills:
☐ Taltz	☐ 80 mg Single Dose Autoinjector ☐ 80 mg Single Dose Prefilled Syringe			Psoriatic Arthritis Dosing and Ankylosing Spondylitis Dosing: Starting Dose: Inject SC two 80 mg injections on Day 1. Maintenance Dose: Inject SC one 80 mg injection every 4 weeks. Non-radiographic Axial Spondyloarthritis Dosing: Dose: Inject SC one 80 mg injection every 4 weeks	Quantity: 2 Pens/Syringes 1 Pens/Syringes Refills:
☐ Tremfya	100 mg/mL prefilled syringe		d	Psoriatic Arthritis Dosing: 100mg administered by SC at Week 0, Week 4 and every 8 weeks thereafter	Quantity:Refills:
☐ Xeljanz	☐ 11 m	g Tablet ng XR Table		☐ Take one 5 mg tablet PO twice daily ☐ Take one 11 mg PO once daily ☐ Other:	Quantity: Refills:
		quired for ROUTE	Home li	nfusion/Coram AIS: DOSE/STRENGTH/DIRECTIONS	QUANTITY/REFILLS
Catheter		mainta PIV – I PORT	eter Care/Flush – Only on drug admin days – SASH or PRN to ain IV access and patency NS 5ml (Heparin 10 units/ml 3-5ml if multiple days) /PICC – NS 10ml & Heparin 100units/ml 3-5ml, and/or 10ml sterile to access port a cath	Quantity:Refills:	
☐ Epinephrine **nursing requires** ☐ IM ☐ Pe ☐ Infa		☐ Adı ☐ Ped ☐ Infa PRN s	ult 1:1000, 0.3mL (>30kg/>66lbs) ds 1:2000, 0.3mL (15-30kg/33-66lbs) ant 0.1mL/0.1mL, 0.1mL (7.5-15kg/16.5-33lbs) evere allergic reaction – Call 911 epeat in 5-15 minutes as needed	Quantity: Refills:	
Patient □ Patie PRODU X	Signature:nt is interested in	patient support progr	ams 6	STAMP SIGNATURE NOT ALLOWED STAMP SIGNATURE NOT ALLOWED PHYSICIAN SIGNATURE REQUIRED (Date) DISPENSE AS WRITTEN X the best of my knowledge, with supporting documentation in the patient's medical re	od for administration Date)

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.